International Journal of Biological Macromolecules, Год журнала: 2024, Номер 289, С. 138800 - 138800
Опубликована: Дек. 16, 2024
Язык: Английский
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 289, С. 138800 - 138800
Опубликована: Дек. 16, 2024
Язык: Английский
Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 9, 2025
This article focusing on examining the function and further, molecular of SHP2 in ovarian cancer (OC). For mechanism, bioinformatics was applied to study specifically expressed genes ; western blotting identify EGF, p-SHP2, ZEB1, E-Cadherin expressions tissue pair adjacent tissue; then SKOV3 cells were treated with EGF infected overexpression lentivirus, benzyl butyl phthalate IRS-1 respectively. Detection expression E-Cadherin, α3-integrin, p-Src, p-SMAD2, Snail, Slug migration invasion abilities detected using Western blot method cell scratch assay Transwell assay; Progression subcutaneous tumor transplantation nude mice HE staining immunocyto. The analysis results suggested that is highly which low tissues, while p-SHP2 or ZEB1 are tissues; Overexpression could reduce Snail might has roles alleviating development decreasing levels samples. And reduced ability cells. tyrosine phosphatase enhances cells' motility invasiveness by upregulation integrin/E-Cadherin switch through signal.
Язык: Английский
Процитировано
0Journal of Experimental & Clinical Cancer Research, Год журнала: 2025, Номер 44(1)
Опубликована: Янв. 24, 2025
Язык: Английский
Процитировано
0Journal of Reproductive Immunology, Год журнала: 2025, Номер 168, С. 104448 - 104448
Опубликована: Фев. 3, 2025
Язык: Английский
Процитировано
0International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(9), С. 4041 - 4041
Опубликована: Апрель 24, 2025
Ovarian cancer is one of the most deadly gynecological cancers, with over 300 thousand new cases per year, which are diagnosed in advanced stages. The limited availability effective biomarkers and lack characteristic symptoms make early diagnosis difficult, resulting a five-year survival rate 30–40%. Mutations BRCA1 BRCA2 genes abnormalities signaling pathways such as PI3K/AKT TP53 play key role progression ovarian cancer. immune system, can act against tumors, often supports tumor development microenvironment through immunoevasion, influenced by cytokines IL-6, IL-10, TGF-β. Epithelial-to-mesenchymal transition (EMT) allows cells to acquire mesenchymal characteristics, increasing their invasiveness metastatic capacity. Immunological factors, including pro-inflammatory signals from regulate EMT process. This review aims present progression, its interactions potential therapeutic targets. Modulation response inhibition may constitute basis for personalized therapies, opens possibilities improving prognosis efficacy treatment patients
Язык: Английский
Процитировано
0Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Май 7, 2025
Ovarian cancer is one of the most lethal gynecological malignancies, with a recurrence rate 70-80%, particularly in patients diagnosed at advanced stages (stage III or IV), where five-year survival falls below 30%. A key driver this presence stem cells (CSCs), which exhibit resistance to chemotherapy and possess capacity for self-renewal, plasticity, tumor regeneration. The microenvironment (TME) plays crucial role maintaining ovarian (OCSCs) by providing nutrient oxygen gradients, extracellular matrix (ECM) interactions, immune cell modulation, support from cancer-associated fibroblasts (CAFs). CAFs secrete growth factors, cytokines, ECM components that create pro-tumorigenic niche, promoting CSC maintenance, invasion, chemoresistance. Additionally, dysregulation critical signaling pathways, including WNT, NOTCH, PI3K/AKT/mTOR, TGF-β, JAK/STAT, Hedgehog, NF-κB, Hippo, supports stemness, adaptability, thereby increasing their progression. Numerous inhibitors targeting these pathways have shown promise preclinical studies. This review discusses molecular mechanisms underlying CSC-mediated highlights emerging therapeutic strategies. Particular emphasis placed on potential combination therapies involving routine platinum taxane based regimens OCSC overcome chemoresistance, reduce rates, improve outcomes advanced-stage cancer.
Язык: Английский
Процитировано
0International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4644 - 4644
Опубликована: Май 13, 2025
ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, has emerged as pivotal tumor suppressor altered in broad range human malignancies. Its frequent inactivation across diverse cancer types revealed pleiotropic roles that intersect multiple Hallmarks Cancer. In this review, we integrate current knowledge on how ARID1A loss influences cellular processes including proliferative signaling, resistance to cell death, genomic instability, metabolic reprogramming, immune evasion, and more. We discuss context-specific consequences deficiency, its cooperation with other oncogenic events, implications for therapeutic vulnerability-particularly realm synthetic lethality modulation. By mapping ARID1A's functional impact onto established hallmarks framework, highlight centrality biology underscore opportunities biomarker-driven strategies targeted interventions. Understanding multifaceted offers compelling lens through which explore dysregulation guide translational advances.
Язык: Английский
Процитировано
0International Journal of Biological Macromolecules, Год журнала: 2024, Номер 289, С. 138800 - 138800
Опубликована: Дек. 16, 2024
Язык: Английский
Процитировано
2